Cystic fibrosis: comorbidity with other serious diseases

Author:

Yankina G. N.1ORCID,Kondratieva E. I.2ORCID,Loshkova E. V.3ORCID,Doroshenko I. V.1ORCID,Rebrienko M. V.1ORCID,Rafikova Yu. S.1ORCID,Bozhenko E. A.1ORCID,Khavkin A. I.4ORCID,Odinaeva N. D.5ORCID,Zhelev V. A.1ORCID,Liulka T. S.1ORCID,Prudnikova V. K.1ORCID

Affiliation:

1. Siberian state medical University

2. Research Centre for Medical Genetics; Reasearch Clinical Institute of Childhood of the Ministry of Health of the Moscow Region

3. Siberian state medical University; Research Centre for Medical Genetics

4. Research Centre for Medical Genetics; Russian National Research Medical University named after N. I. Pirogov

5. Research Centre for Medical Genetics

Abstract

Numerous epidemiological studies demonstrate that cystic fibrosis, the most common orphan disease in the world, can not occur in isolation, but can be combined with other serious diseases. The most common such combination in all populations is traditionally cystic fibrosis and celiac disease, which, on the one hand, differ in the leading mechanism of inflammation, in cystic fibrosis - chronic microbial inflammation, in celiac disease - autoimmune, on the other hand, these two diseases have a number of common pathogenesis links, in particular, realizing the syndrome of malabsorption, which only complicates the timely diagnosis of these combined pathological conditions. In addition, the authors of the literature review focus on clinical examples of late detection of autoimmune gluten intolerance against the background of cystic fibrosis. They also consider the combination of cystic fibrosis with other severe, disabling diseases (rheumatoid arthritis, phenylketonuria, oncological diseases), which sometimes require a serious change in therapeutic tactics.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference73 articles.

1. Register of patients with cystic fibrosis in the Russian Federation 2020/ Edited by E. I. Kondratiev, S. A. Krasovsky, M. A. Starinova, A. Yu. Voronkov, E. L. Amelina, N. Yu. Kashirskaya, S. N. Avdeev, S. I. Kutsev . Moscow. ID "MEDPRAKTIKA-M", 2022, 68 p.@@ Registr patsientov s mukovistsidozom v Rossiiskoi Federatsii. 2020 god. / Pod redaktsiei E. I. Kondrat'evoi, S. A. Krasovskogo, M. A. Starinovoi, A. Yu. Voronkovoi, E. L. Amelinoi, N. Yu. Kashirskoi, S. N. Avdeeva, S. I. Kutseva. - M.: ID «MEDPRAKTIKA-M», 2022, 68 s. ISBN 978-5-98803-456-8.

2. Saluzzo F, Riberi L, Messore B, Loré NI, Esposito I, Bignamini E, De Rose V. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells. 2022 Apr 6;11(7):1243. doi: 10.3390/cells11071243. PMID: 35406809; PMCID: PMC8998122.

3. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O’Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Erratum in: Lancet Respir Med. 2019 Dec;7(12): e40. PMID: 31570318; PMCID: PMC8862661.

4. Choong E, Sauty A, Koutsokera A, Blanchon S, André P, Decosterd L. Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now? Pharmaceutics. 2022 Aug 11;14(8):1674. doi: 10.3390/pharmaceutics14081674. PMID: 36015300; PMCID: PMC9412421.

5. Gavillet H, Hatfield L, Rivett D, Jones A, Maitra A, Horsley A, van der Gast C. Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis. Microbiol Spectr. 2022 Oct 26;10(5): e0041922. doi: 10.1128/spectrum.00419-22. Epub 2022 Aug 16. PMID: 35972283; PMCID: PMC9602735.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3